Jump to Main Content
Performance of commercially available serological diagnostic tests to detect Leishmania infantum infection on experimentally infected dogs
- Rodríguez-Cortés, Alhelí, Ojeda, Ana, Todolí, Felicitat, Alberola, Jordi
- Veterinary parasitology 2013 v.191 no.3-4 pp. 363-366
- Leishmania donovani, Leishmania infantum, antibodies, dogs, enzyme-linked immunosorbent assay, etiological agents, humans, leishmaniasis, odds ratio, risk reduction, zoonoses
- Leishmania infantum (syn. Leishmania chagasi) is the etiological agent of a widespread serious zoonotic disease that affects both humans and dogs. Prevalence and incidence of the canine infection are important parameters to determine the risk and the ways to control this reemergent zoonosis. Unfortunately, there is not a gold standard test for Leishmania infection. Our aim was to assess the operative validity of commercial tests used to detect antibodies to Leishmania in serum samples from experimental infections. Three ELISA tests (LEISCAN® Leishmania ELISA Test, INGEZIM® LEISHMANIA, and INGEZIM® LEISHMANIA VET), three immunochromatographic tests (INGEZIM® LEISHMACROM, SNAP® Leishmania, and WITNESS® Leishmania), and one IFAT were evaluated. LEISCAN® Leishmania ELISA test achieved the highest sensitivity and accuracy (both 0.98). Specificity was 1 for all tests except for IFAT. All tests but IFAT obtained a positive predictive value of 1, while the maximum negative predictive value was achieved by LEISCAN® Leishmania ELISA Test (0.93). The best positive likelihood ratio was obtained by INGEZIM® LEISHMANIA VET (30.26), while the best negative likelihood ratio was obtained by LEISCAN® Leishmania ELISA Test (0.02). The highest diagnostic odds ratio was achieved by LEISCAN® Leishmania ELISA Test (729.00). The largest area under the ROC curve was obtained by LEISCAN® Leishmania ELISA Test (0.981). Quantitative ELISA based tests performmed better than qualitative tests (“Rapid Tests”), and the test best suited to detect Leishmania in infected dogs and to provide clinically useful information was LEISCAN® Leishmania ELISA Test. This and other results point also to the need of revising the status of IFAT as a gold standard for the diagnosis of leishmaniasis.